BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8381228)

  • 1. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
    Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
    Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers.
    Strauch G; Perles P; Vergult G; Gabriel M; Gibelin B; Cummings S; Malbecq W; Malice MP
    Eur Urol; 1994; 26(3):247-52. PubMed ID: 7805711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
    Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
    Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
    Geller J; Sionit L
    J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
    Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
    J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat.
    George FW; Johnson L; Wilson JD
    Endocrinology; 1989 Nov; 125(5):2434-8. PubMed ID: 2551651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects.
    Giudici D; Briatico G; Cominato C; Zaccheo T; Iehlè C; Nesi M; Panzeri A; di Salle E
    J Steroid Biochem Mol Biol; 1996 Jun; 58(3):299-305. PubMed ID: 8836165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
    Habib FK; Ross M; Ho CK; Lyons V; Chapman K
    Int J Cancer; 2005 Mar; 114(2):190-4. PubMed ID: 15543614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
    Stoner E
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
    di Salle E; Giudici D; Radice A; Zaccheo T; Ornati G; Nesi M; Panzeri A; Délos S; Martin PM
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):179-86. PubMed ID: 9605412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
    Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
    Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
    Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
    J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat.
    di Salle E; Giudici D; Biagini L; Cominato C; Briatico G; Panzeri A
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):381-5. PubMed ID: 7626485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
    Rittmaster RS; Stoner E; Thompson DL; Nance D; Lasseter KC
    J Androl; 1989; 10(4):259-62. PubMed ID: 2550402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate.
    Rittmaster RS; Magor KE; Manning AP; Norman RW; Lazier CB
    Mol Endocrinol; 1991 Jul; 5(7):1023-9. PubMed ID: 1719382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque.
    Diani AR; Mulholland MJ; Shull KL; Kubicek MF; Johnson GA; Schostarez HJ; Brunden MN; Buhl AE
    J Clin Endocrinol Metab; 1992 Feb; 74(2):345-50. PubMed ID: 1309834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.
    Brooks JR; Berman C; Nguyen H; Prahalada S; Primka RL; Rasmusson GH; Slater EE
    Prostate; 1991; 18(3):215-27. PubMed ID: 1850515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.